

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alcassedan, Virginia 22313-1450 www.emplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/614,964	07/08/2003	Hector F. DeLuca	1256-00777	8876	
26753 ANDRUS, SCEALES, STARKE & SAWALL, LLP 100 EAST WISCONSIN AVENUE, SUITE 1100			EXAMINER		
			MCMILLIAN, KARA RENITA		
MILWAUKEI	∃, W1 53202	ART UNIT	PAPER NUMBER		
			1617		
			MAIL DATE	DELIVERY MODE	
			07/21/2009	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

# Office Action Summary

Application No.	Applicant(s)	
10/614,964	DELUCA ET AL.	
Examiner	Art Unit	
KARA R. MCMILLIAN	1617	

		KARA R. MCMILLIAN	1617				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHO WHICH - Extens after S - If NO p - Failure Any re	PRIENED STATUTORY PERIOD FOR REPLY HEVER IS LONGER, FROM THE MAILING D. VIOLEN of them may be available under the provisions of 37 CFR 1.13 (K (6) MONTHS from the mailing date of this communication. The control for reply is appoinful above. The maximum situation period we describe the provision of 37 CFR 1.13 (K (6) MONTHS from the mailing date of this control for the provision of 37 CFR 1.13 (K (6) MONTHS from the mailing date of the mailing patient trem displanett. See 37 CFR 1.74(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from 1 cause the application to become ABANDONEI	L.  ely filed the mailing date of this of (35 U.S.C. § 133).	,			
Status							
2a)□ -	Responsive to communication(s) filed on <u>10 Fe</u> This action is <b>FINAL</b> . 2b)⊠ This Since this application is in condition for allowar	action is non-final.	secution as to the	e merits is			
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositio	on of Claims						
	Claim(s) <u>1-39</u> is/are pending in the application. a) Of the above claim(s) <u>1-21 and 23-39</u> is/are						
	Claim(s) is/are allowed.	william nom consideration.					
	Claim(s) 22 is/are rejected.						
	Claim(s) is/are objected to.						
	Claim(s) are subject to restriction and/or	r election requirement.					
Application	n Papers						
9)□⊤	he specification is objected to by the Examine	r.					
	'he drawing(s) filed on is/are: a) ☐ acce		Examiner.				
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	Replacement drawing sheet(s) including the correcti			FR 1.121(d).			
_	he oath or declaration is objected to by the Ex						
Priority u	nder 35 U.S.C. § 119						
a)[	cknowledgment is made of a claim for foreign All b) Some * c) None of:		-(d) or (f).				
	1. Certified copies of the priority documents have been received.						
	Certified copies of the priority documents have been received in Application No      Copies of the certified copies of the priority documents have been received in this National Stage						
,	application from the International Bureau	•	d in this National	Stage			
* 94	• •		d				
36	* See the attached detailed Office action for a list of the certified copies not received.						
Attachment	s)						
	of References Cited (PTO-892)	4) Interview Summary					
2) Notice	of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da					

Attachment(s)		
Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413)	
Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date	
3) Information Disclosure Statement(s) (PTO/35/08)	5). Notice of Informal Patert Application.	
Paper No/e)/Mail Date	6) Other:	

#### DETAILED ACTION

Claims 1-39 are pending.

## Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on February 10, 2009 has been entered.

## Response to Amendments/ Arguments

Applicants have made no amendments to the claims. Claims 1-21 and 23-39 remain withdrawn. Claim 22 is presented for examination.

Applicant's arguments filed February 10, 2009, with respect to the rejection of claim 22 under 35 USC 103 have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground of rejection is made in view of Deluca et al. U.S. Patent No. 5,843,928 (see below).

### Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Application/Control Number: 10/614,964

Art Unit: 1617

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 22 is rejected under 35 U.S.C. 102(b) as being anticipated by Deluca et al.

U.S. Patent No. 5,843,928 (provided on IDS).

Claim 22 of the instant application claims the compound (20S)- $1\alpha$ -hydroxy-2-methylene-19-nor-vitamin  $D_3$  having the formula:

Deluca et al. claim a novel class of vitamin D related compounds, namely, the 2alkylidiene-19-nor-vitamin D derivatives (see abstract). Claim 1 of Deluca et al. claims a compound having the formula: Application/Control Number: 10/614,964 Art Unit: 1617

where  $Y_1$  and  $Y_2$  are selected from the group consisting of hydrogen and a hydroxyl-protecting group and  $R_6$  and  $R_8$  are selected from hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or when taken together represent the group —(CH2)<sub>x</sub>, where x is an integer from 2 to 5. Claim 8 of Deluca et al. claims the compound of claim 1 where R is a side chain of the formula:

Applicant's claimed compound is exemplified in claim 8 of Deluca et al. when  $Y_1$ ,  $Y_2$ ,  $R_6$  and  $R_8$  are all hydrogen. The compound of instant claim 22 is anticipated since

Application/Control Number: 10/614,964

Art Unit: 1617

an ordinary skilled artisan would be able to clearly envisage Applicant's claimed compound from Deluca et al. since and the  $Y_1$ ,  $Y_2$ ,  $R_6$  and  $R_8$  genus are limited, thus very few combinations can be obtained. Please note that if one of ordinary skill in the art is able to "at once envisage" the specific compound within the generic chemical formula, the compound is anticipated. One of ordinary skill in the art must be able to draw the structural formula or write the name of each of the compounds included in the generic formula before any of the compounds can be "at once envisaged." One may look to the preferred embodiments to determine which compounds can be anticipated. *In re Peterina*. 301 F.2d 676, 133 USPQ 275 (CCPA 1962).

#### Conclusions

Claim 22 is rejected. Claims 1-21 and 23-39 are withdrawn. No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to KARA R. MCMILLIAN whose telephone number is (571)270-5236. The examiner can normally be reached on Monday-Thursday from 8:30 am- 6:00 pm and every other Friday from 8:30 am- 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571)272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/614,964 Page 6

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Kara R. McMillian/ Examiner, Art Unit 1617

KRM

/SREENI PADMANABHAN/

Supervisory Patent Examiner, Art Unit 1617